Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
Putin and Modi discuss trade, peace in New Delhi summit
Indian air travel crippled as IndiGo's pilot crisis enters fourth day
Lebanon says ceasefire talks aim primarily at halting Israel's hostilities
US to widen travel ban to more than 30 countries, Noem says
Putin visits Delhi as Russia, India seek to increase and diversify trade
